WVE Wave Life Sciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1631574 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-72.6%
TTM EPS YoY-64.6%
Revenue 3-yr CAGR-6.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-320.9%
Net margin-296.9%
FCF margin-293.8%
EBITDA margin-316.1%
Returns
ROE-80.0%
ROA-56.2%
ROIC (approx.)-270.5%
Asset turnover0.19x
Leverage & solvency
Liabilities / assets20.9%
Debt / equity0.00x
Current ratio8.38x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.98x
Accruals ratio-0.9%
Payout ratio—
Capex / revenue1.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $13.16M | $2.27M | $38.25M | $17.25M | $7.61M | $8.70M | $9.18M | — |
| R&D expense | $53.84M | $51.29M | $47.44M | $52.81M | $45.87M | $43.47M | $40.62M | $44.65M |
| SG&A expense | $25.36M | $24.78M | $22.10M | $20.90M | $18.09M | $17.99M | $18.36M | $16.14M |
| Operating income | -$66.05M | -$73.80M | -$31.30M | -$56.47M | -$56.35M | -$52.76M | -$49.80M | $22.97M |
| Pretax income | -$61.91M | -$69.36M | -$26.09M | -$53.18M | -$53.85M | -$50.47M | -$46.88M | $29.25M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$61.91M | -$69.36M | -$26.09M | -$53.18M | -$53.85M | -$50.47M | -$46.88M | $29.25M |
| EBITDA | -$65.17M | -$72.94M | -$30.46M | -$55.62M | -$55.50M | -$51.89M | -$48.93M | $23.87M |
| EPS (basic) | -0.30 | -0.34 | -0.13 | — | -0.32 | -0.31 | -0.29 | — |
| EPS (diluted) | -0.30 | -0.34 | -0.13 | — | -0.32 | -0.31 | -0.29 | — |
| Weighted avg. shares (diluted) | 204.22M | 204.01M | 200.17M | — | 167.74M | 163.99M | 162.57M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $197.31M | $368.01M | $544.59M | $602.07M | $196.22M | $208.48M | $243.07M | $302.08M |
| Short-term investments | $233.43M | — | — | $0 | — | — | — | — |
| Receivables | $12.00M | $888,000 | $0 | $1.28M | $10.00M | $1.62M | — | $1.42M |
| Current assets | $458.63M | $507.51M | $561.27M | $614.81M | $215.49M | $223.56M | $257.98M | $320.39M |
| PP&E, net | $6.24M | $6.83M | $7.08M | $7.41M | $8.20M | $9.04M | $9.57M | $10.13M |
| Total assets | $507.93M | $558.32M | $583.54M | $638.50M | $241.38M | $252.35M | $288.34M | $352.21M |
| Current liabilities | $54.76M | $50.81M | $49.83M | $95.06M | $85.90M | $87.41M | $87.37M | $110.95M |
| Total liabilities | $105.99M | $104.80M | $71.81M | $112.27M | $108.95M | $105.22M | $108.67M | $134.82M |
| Shareholders' equity | $401.94M | $453.52M | $511.73M | $518.36M | $124.55M | $139.27M | $171.80M | $209.51M |
| Shares outstanding | 197.21M | 193.28M | 192.34M | 0 | 160.29M | 155.67M | 154.09M | 153.04M |
| Cash flow statement | ||||||||
| Operating cash flow | -$60.14M | -$53.58M | -$59.55M | -$33.78M | -$44.67M | -$46.01M | -$63.04M | -$43.65M |
| Capital expenditure | $15,000 | $884,000 | $438,000 | -$1,000 | $248,000 | $306,000 | $165,000 | $86,000 |
| Free cash flow | -$60.16M | -$54.47M | -$59.99M | -$33.77M | -$44.91M | -$46.32M | -$63.20M | -$43.73M |
| Investing cash flow | -$110.86M | -$123.45M | -$438,000 | $1,000 | -$248,000 | -$306,000 | -$165,000 | -$86,000 |
| Financing cash flow | $433,000 | $330,000 | $2.53M | $439.69M | $32.69M | $11.69M | $4.16M | $34.98M |
| Depreciation & amortization | $880,000 | $858,000 | $841,000 | $844,000 | $856,000 | $865,000 | $875,000 | $907,000 |
| Stock-based compensation | $10.29M | $10.73M | $9.06M | $7.35M | $6.47M | $6.20M | $4.95M | $3.24M |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.